通產麗星(002243.SZ):19.06億元聯合競得蘇州太倉市三宗商住地
格隆匯12月20日丨通產麗星(002243.SZ)公佈,公司全資子公司力合科創與仁恆置地及其全資孫公司仁琢置業在太倉市自然資源和規劃局舉辦的國有土地使用權網上掛牌出讓活動中,以人民幣19.0561億元競得編號2019-WG-22-3、2019-WG-22-4、2019-WG-22-5地塊的國有土地使用權,並於2019年12月19日取得了《掛牌交易成交確認書》。
宗地2019-WG-22-3、2019-WG-22-4、2019-WG-22-5位於蘇州太倉市高新區江申大道西、桴亭路北;用地性質為商業、城鎮住宅、地下空間;建設用地面積合計約為17.43萬平方米。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.